Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

gonadorelin
growth factor
glomerular filtration rate
renal function tests
metastatic castration-resistant prostate cancer
  • 0 views
  • 19 Feb, 2024
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

stereotactic body radiation therapy
adenocarcinoma
adenocarcinoma of prostate
  • 0 views
  • 19 Feb, 2024
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the …

extracapsular extension
gonadorelin
immunological adjuvant
adenocarcinoma of prostate
hypofractionated radiation therapy
  • 0 views
  • 19 Feb, 2024
HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

brachytherapy
pet/mri
local therapy
  • 0 views
  • 19 Feb, 2024
Interactive Decision Aid for Men Diagnosed With Prostate Cancer

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).

cancer diagnosis
  • 0 views
  • 19 Feb, 2024
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

definitive treatment
adenocarcinoma of prostate
ct scan
tumor progression
hormone therapy
  • 0 views
  • 19 Feb, 2024
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

prostate specific antigen
conventional imaging
pet/mri
metastasis
molecular imaging
  • 0 views
  • 19 Feb, 2024
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

This increasingly allows individualized specific therapy of patients with prostate cancer recurrence. PSMA PET has now been included in national and international guidelines for the diagnosis of patients with biochemical recurrence of prostate cancer.

cancer recurrence
prostate specific antigen
prostatectomy
lymphadenectomy
metastasis
  • 0 views
  • 19 Feb, 2024
Evaluation of a Virtual Reality Tool for Identifying the Cognitive Functions of the Right Hemisphere in Patients With Glioma -TANGO

Evaluate the diagnostic performance of a virtual reality application to detect the presence of cognitive impairment of the non-dominant hemisphere in patients with glioma

cognitive impairment
  • 0 views
  • 19 Feb, 2024
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or …

antiandrogen therapy
androgens
adenocarcinoma of prostate
recurrent prostate cancer
androgen deprivation
  • 0 views
  • 19 Feb, 2024